A new fascinating addition to Menicon Bloom™ Easyfit professional software has been released: the Quick Workflows.

At Menicon, we consider myopia control treatments as clinical interventions. On the professional platform, Menicon Bloom™ Easyfit, comprehensive workflows with the main recommended tests for each visit can be found. They are called Guided Workflows. Menicon strongly recommends their use for a holistic approach.

However, there may be different ways of working, levels of knowledge, or specific circumstances for each fitting at certain times. The new Quick Workflow option may be of interest in those cases.

This feature offers a shorter New Initial Measurement Visit to simply calculate Menicon Bloom™ lenses, plus offering a Quick Difference Map Assessment visit and the Lens Reorder option.

Switching the type of workflow at any time on any patient on Menicon Bloom™ Easyfit is now possible.

With an unwavering commitment to upholding our high-quality standards, Menicon is continuously working to integrate new features to bring additional advantages to Menicon Bloom™ system performance.

Menicon Bloom took home the Contact Lens Award at 30th November 2022 Optician Awards in London. 

Recognised in the category for its global industry-leading innovation and commitment to improving myopia management, Menicon Bloom offers a truly comprehensive treatment plan for childhood myopia.

The Menicon Bloom plan features a holistic approach to Myopia: state-of-the-art fitting software for ECPs and an innovative app for patients, to ease the information collection and fitting and also to facilitate communication between both parties. It also includes all the tools for the ECP to have a successful myopia journey with their patients and two contact lenses that are CE approved specifically for myopia control: Menicon Bloom Night, a specially designed orthokeratology contact lens, with its own Menicon Bloom lens care solutions, and Menicon Bloom Day, an extended depth of focus soft daily disposable contact lens.

Celebrating the win, and speaking on behalf of the entire Menicon Global team who have been involved in developing Menicon Bloom, Kevin Mitchell, Managing Director at Menicon UK, said: “To take home the Contact Lens Award for Menicon Bloom is not only a fantastic achievement, it’s also real recognition of the hard work and innovation which has gone into creating a treatment plan for something which impacts a huge percentage of the world’s population. 

“With forecasts predicting levels of world myopia could increase to 50% by 2050*¹, the threat to our children’s eyesight is very real. We recognise the alarming challenges that rising levels of childhood myopia present and have successfully developed and rolled out a solution. Menicon Bloom has the potential to be truly transformational in the way we treat and manage this condition. 

“The Menicon Bloom family provides all-day versatility, comfort and peace of mind to children, young people and their families. It integrates well into the child’s everyday life and becomes a hassle-free part of their daily routine. For parents and ECPs, we’ve streamlined the process by ensuring that all of the information they need is available via our app and our system, Menicon Bloom Easyfit, respectively, which makes the whole experience less stressful and more efficient.

“Menicon is more than just a brand, it is an ethical business that puts the needs of ECPs and patients at the heart of everything that it does.”

Menicon was praised for going above and beyond to support ECPs who have recommended a myopia management journey for their patients, from fitting, using its advanced Menicon Bloom Easyfit software and the innovative Menicon Bloom app, to understanding the importance of engaging the child and their family throughout their journey.

The Menicon Bloom system is tailored so that it can be easily managed by children, giving them the ability to take a hands-on approach in the insertion, removal and caring of their contact lenses.

*¹ Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.

The launch demonstrates the company’s continued commitment to offering on-label, approved products specifically for myopia control management to patients and eye care practitioners worldwide. 

Menicon Co., Ltd. is pleased to announce the launch of Menicon Bloom™, a holistic treatment plan for myopia control in seven additional markets worldwide together with a powerful and impressive marketing campaign titled “See Their Imagination Bloom”.

Myopia, also known as near- or short-sightedness, is a common refractive error and one of the major causes of vision impairment worldwide. It affects approximately 30% of the world’s population and its prevalence has been forecast to affect about 50% of the world’s population by 2050. The prevalence of myopia in young adolescents has been increasing in recent decades to about 30% in industrialized societies of the West and epidemic levels of over 90% in some parts of Far East Asia. Globally, it is recognized as a significant public health concern associated with increased ocular-related morbidity and considerable healthcare costs.

Concerned with the growing incidence of myopia and its health consequences worldwide, Menicon Co., Ltd. has developed Menicon Bloom™, a comprehensive treatment plan for childhood myopia that features two contact lenses that are CE-approved specifically for myopia control: Menicon Bloom Night™, a specially designed orthokeratology contact lens, and Menicon Bloom Day™, an extended depth of focus soft daily disposable contact lens. Combined with specially formulated Menicon Bloom™ lens care solutions, state-of-the-art fitting software and an innovative Menicon Bloom™ app, this holistic treatment plan helps slow down the progression of childhood myopia while providing all the tools for a successful myopia journey.

Menicon Bloom™ was first introduced in the Netherlands in 2019. With this additional release, Menicon will launch across the United Kingdom, France, Spain, Italy, Austria, Australia, and Singapore starting March 2022. The launch demonstrates the company’s continued commitment to offering on-label, approved products specifically for myopia control management to patients and eye care practitioners worldwide. 

The launch is being enhanced with an exciting marketing campaign titled “See Their Imagination Bloom” to raise awareness of childhood myopia and its possible treatment options. With a rich and vibrant visual world of imagination, the campaign aims to make it reassuringly easy for parents and eye care professionals around the world to incorporate the Menicon Bloom™ treatment plan into children’s daily routines.

Please contact your local Menicon representative to get more information on the availability of Menicon Bloom™ in your country.

About Menicon Co., Ltd.

Menicon Co., Ltd. (7780: Tokyo), founded by Mr. Kyoichi Tanaka in 1951, is Japan’s first and largest contact lens manufacturer, and is represented in over 80 countries. Menicon is a manufacturer dedicated to all areas of soft and gas-permeable contact lens-related businesses including manufacturing, sales, export and import of contact lenses and other medical goods; manufacturing and sales of medical instruments; sales of medical supplies; and research and development of intraocular lenses. For more information, please visit: https://www.menicon.com/

Nagoya, Japan – [April 7, 2021] – Menicon, a leading manufacturer of innovative contact lenses and related products, today announced a global strategic collaboration with Johnson & Johnson Vision*, a global leader in eye health. Following the 2019 launch of the Menicon Bloom Myopia Control Management System in Europe, this collaboration will further strengthen Menicon’s commitment to help society combat the rising Myopia epidemic.

Myopia, or nearsightedness, has traditionally been viewed as an ocular inconvenience, once associated with scholars and those who pursued a predominantly indoor and education driven path. Myopia treatment has typically involved usage of optical devices such as spectacles or contact lenses and its purpose, simply to correct the patient’s vision. Modern myopia, however is an aggressively evolving disease and is projected to affect half the world’s population over the coming three decades. The most vulnerable to this disease in our society are children in which myopia progression is impacting their prospective visual and health outcomes due to increased risks of sight-threatening ocular pathologies, such as retinal detachments.

“Epidemiological evidence from all around the globe continues to show the remarkable increase in the percentage of children and young adults developing myopia, and the earlier age at which myopia starts,” said Professor Lyndon Jones, DSc, PhD, FCOptom. “This global epidemic comes with substantial risks of vision loss later in life and continued education on the importance of early intervention to manage the progression of myopia and the development of novel methods to reduce it have never been more important.”

As part of the collaboration, Johnson & Johnson Vision will focus on expanding availability of the lenses around the world . Menicon will develop and manufacture the therapeutic contact lenses to manage the progression of myopia in children while continuing to support its current and new customers.

“Menicon has a long history of safety and innovation in the contact lens field and we continue to explore and invest in new ways to positively impact our patients’ lives” said Dr. Hidenari Tanaka, President, Menicon Co. Ltd. “Our partnership with Johnson & Johnson is a wonderful opportunity to expand and realize our potential to effectively address the progression of myopia in children worldwide.  A strategic collaboration such as this will be beneficial, particularly with an incredible company that shares our vision for the future, our high standards for safety and our common core values.”

For eye care providers who want to learn more about products and services from Menicon to help manage the progression of myopia, please visit us at:

https://www.menicon.com/corporate/news/view/49

https://www.menicon.com/corporate/news/view/4

About Menicon Co. Ltd.

Menicon Co., Ltd. (7780: Tokyo), founded by Mr. Kyoichi Tanaka in 1951, is Japan’s first and largest contact lens manufacturer, and now is represented in over 80 countries. Menicon is a manufacturer dedicated to all areas of soft and gas permeable contact lens-related businesses including manufacturing, sales, export and import of contact lenses and other medical goods; manufacturing and sales of medical instruments; sales of medical supplies; and research and development of intraocular lenses.

For more information, please visit us: www.menicon.com.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

With this addition, Menicon is the only company in the world offering both orthokeratology and soft contact lens devices specifically approved for myopia control in Europe

NAGOYA, Japan, 16 October 2019 – Menicon Co., Ltd announces it has entered into a definitive agreement with Visioneering Technologies, Inc (VTI) to market and sell VTI’s NaturalVue® MF contact lenses in Europe. NaturalVue® MF (etafilcon A) center-distance multifocal daily disposable soft (hydrophilic) contact lenses are indicated for daily wear for the correction of refractive myopia and myopia progression control in non-aphakic persons with non-diseased eyes in powers up to -12 diopters and will be commercialized by Menicon in Europe as Menicon Bloom™ Day under the Menicon Bloom™ Myopia Control Management System.

The above announcement shortly follows the recent launch of Menicon Bloom™ Myopia Control Management System in the Netherlands last June, which featured the initial introduction of Menicon Bloom™ Night, the first and only CE-approved orthokeratology contact lens in Europe for myopia control. With the addition of Menicon Bloom™ Day to Menicon Bloom™ Myopia Control Management System, Menicon is the only company in the world offering both orthokeratology and soft contact lens devices specifically approved for myopia control in Europe and demonstrates the company’s continued commitment to the field of myopia control. Full launch of Menicon Bloom™ Myopia Control Management System will be expected in major European markets throughout 2020.

Dr. Hidenari Tanaka, CEO, Menicon Co., Ltd., commented: “We are delighted with the addition of VTI’s NaturalVue® MF daily disposable contact lenses to our Menicon Bloom™ Myopia Control Management System. We are committed to building a strong and flexible product portfolio within our Menicon Bloom™ Myopia Control Management System in order to offer eye care professionals worldwide a wide range of on-label, approved treatment options for myopia control. We believe the increasing levels of myopia reported across the world requires a comprehensive and educated response and we have identified this as a major initiative within our development programs.”
* “Bloom”, “Bloom Night” and “Bloom Day” are trademarks of Menicon Co., Ltd.

About Menicon:
Menicon Co., Ltd. (7780: Tokyo), founded by Mr. Kyoichi Tanaka in 1951, is Japan’s first and largest contact lens manufacturer, and now is represented in over 30 countries. Menicon is a manufacturer dedicated to all areas of soft and gas permeable contact lens-related businesses including manufacturing, sales, export and import of contact lenses and other medical goods; manufacturing and sales of medical instruments; sales of medical supplies; and research and development of intraocular lenses.
For more information, visit: www.menicon.com.

About Visioneering
Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism. Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® MF daily disposable contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.
To learn more, please visit: www.vtivision.com